加载中
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
收盘时
US$2.45
−US$0.03 · -1.21%
盘后
US$2.40
−US$0.05 · -2.04%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
日内区间
当前US$2.45
52周区间
当前US$2.45
盘中时间采用ET。市场数据可能有所延迟。
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
日内区间
当前US$2.45
52周区间
当前US$2.45
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 119.9万 USD | 239.2万 USD | 70.9万 USD | 122.2万 USD | 130.6万 USD |
| 销货成本 | 39.6万 USD | 50.8万 USD | 48.8万 USD | 72.5万 USD | 71.6万 USD |
| 毛利 | 80.3万 USD | 188.4万 USD | 22.1万 USD | 49.7万 USD | 59万 USD |
| 研究与开发 | 1204.1万 USD | 813.7万 USD | 906.6万 USD | 937万 USD | 709.2万 USD |
| 销售、一般及管理费用 | 1204.9万 USD | 1026.9万 USD | 1218.4万 USD | 917万 USD | 1095.4万 USD |
| 营业费用 | 2409万 USD | 1840.6万 USD | 2125万 USD | 1854万 USD | 1804.6万 USD |
| 利息支出 | — | — | — | — | 4000 USD |
| 折旧和摊销 | 122.6万 USD | 95.8万 USD | 94.6万 USD | 89.3万 USD | 91.4万 USD |
| 营业利润 | −2328.7万 USD | −1652.2万 USD | −2102.9万 USD | −1804.3万 USD | −1745.6万 USD |
| 净利润 | −2270.4万 USD | −1597.3万 USD | −2141.3万 USD | −1883.5万 USD | −1704.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$10.00
上涨空间 308.16%评级样本有限，仅4项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月27日 | 1:10 | — | — |
股票拆分 | 2024年3月27日 | 1:10 | — | — |
已生效 2026年8月27日
1:10
已生效 2024年3月27日
1:10
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
